Document Detail


Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
MedLine Citation:
PMID:  18076664     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-alpha blocker therapy. All TB cases (n = 21) complicating TNF-alpha blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-alpha antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-alpha antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed.
Authors:
B Denis; A Lefort; R M Flipo; F Tubach; M Lemann; P Ravaud; D Salmon; X Mariette; O Lortholary;
Related Documents :
21963244 - Evaluation of bee venom and hyaluronic acid in the intra-articular treatment of osteoar...
8729624 - Treatment of acute, uncomplicated, falciparum malaria with oral dihydroartemisinin.
7304664 - Invasive aspergillosis of the lung and pericardium in a nonimmunocompromised 33 year ol...
6099224 - Topical ketoconazole (2% dermatological cream) for the treatment of superficial dermato...
23011674 - Importance of occlusal plane reproduction on the semi-adjustable articulator in plannin...
25299554 - Effectiveness of post-pyloric tube placement using magnetic guidance.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-12-10
Journal Detail:
Title:  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases     Volume:  14     ISSN:  1198-743X     ISO Abbreviation:  Clin. Microbiol. Infect.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-10     Completed Date:  2008-09-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9516420     Medline TA:  Clin Microbiol Infect     Country:  France    
Other Details:
Languages:  eng     Pagination:  183-6     Citation Subset:  IM    
Affiliation:
Université Paris V, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Antirheumatic Agents / adverse effects*,  therapeutic use
Antitubercular Agents / therapeutic use
Arthritis, Rheumatoid / complications,  drug therapy*
Female
Follow-Up Studies
France / epidemiology
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use
Male
Middle Aged
Questionnaires
Treatment Outcome
Tuberculosis / chemically induced*,  drug therapy,  mortality
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Antitubercular Agents; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of the Vitek-2 extended-spectrum beta-lactamase test against non-duplicate strains of Ent...
Next Document:  Use of a multiplex PCR-based reverse line blot (mPCR/RLB) hybridisation assay for the rapid identifi...